




# Lecture 2: Training requirements for ML

*Issam El Naqa, PhD*

# What is AI/ML/DL?



El Naqa, BJR 125<sup>th</sup> Annv., 2020

## Artificial Intelligence

Originated in the 1950s

Build machines that think like humans



## Machine Learning

Originated in the 1960s


Computer algorithms that learn from data



## Deep Learning

Originated in the 1970s

Based on neural networks that learn features





# The Universe of Machine Learning (ML)



Adapted from: Brownlee, 2013



# Deep vs conventional machine learning




Machine and Deep Learning in Oncology, Medical Physics and Radiology

Issam El Naqa  
Martin J. Murphy  
Editors


Second Edition

Springer

# Neural Networks Past and Present




S. McCulloch - W. Pitts



- Adjustable Weights
- Weights are not Learned



F. Rosenblatt




- Learnable Weights and Threshold



B. Widrow - M. Hoff




M. Minsky - S. Papert



- XOR Problem




D. Rumelhart - G. Hinton - R. Williams



- Solution to nonlinearly separable problems
- Big computation, local optima and overfitting




V. Vapnik - C. Cortes



- Limitations of learning prior knowledge
- Kernel function: Human Intervention



G. Hinton - S. Ruslan



- Hierarchical feature Learning



# Learning ML advice



**Shane Legg**

@ShaneLegg

Follow



Learn:

1. linear algebra well (e.g. matrix math)
2. calculus to an ok level (not advanced stuff)
3. prob. theory and stats to a good level
4. theoretical computer science basics
5. to code well in Python and ok in C++

Then read and implement ML papers and  
\*play\* with stuff! :-)

**aron** @aron65900682

@ShaneLegg Hey Shane I'm currently 17 from London England and am very passionate about AI, also learning about in-depth human needs. What would be the 5 pieces of advice and tips you would give to a young person like me?

# Regression methods

Regression model is:

$$Y \sim \text{Model}(X\beta)$$

Model: linear, logit, probit

➤  $X_1, X_2, \dots, X_n$  **linearly additive**


➤ Y and X have a **monotonic** relationship

- Ordinary estimation (no penalty)
- Regularization (shrinkage) estimation:


- Ridge 
$$Y \sim \text{Model}(X\beta) + \lambda \sum_i \beta_i^2$$

- Lasso 
$$Y \sim \text{Model}(X\beta) + \lambda \sum_i |\beta_i|$$

- Estimation methods: Least-squares, maximum likelihood



# Deep learning with Neural Networks




*The key aspect of deep learning is that these layers of features are not designed by human engineers: they are learned from data using a general-purpose learning procedure*

Rumelhart, 1986



# Biological versus Artificial Neuron



Name	Plot	Equation	Derivative
Identity		$f(x) = x$	$f'(x) = 1$
Binary step		$f(x) = \begin{cases} 0 & \text{for } x < 0 \\ 1 & \text{for } x \geq 0 \end{cases}$	$f'(x) = \begin{cases} 0 & \text{for } x \neq 0 \\ ? & \text{for } x = 0 \end{cases}$
Logistic (a.k.a Soft step)		$f(x) = \frac{1}{1 + e^{-x}}$	$f'(x) = f(x)(1 - f(x))$
Tanh		$f(x) = \tanh(x) = \frac{2}{1 + e^{-2x}} - 1$	$f'(x) = 1 - f(x)^2$
ArcTan		$f(x) = \tan^{-1}(x)$	$f'(x) = \frac{1}{x^2 + 1}$
Rectified Linear Unit (ReLU)		$f(x) = \begin{cases} 0 & \text{for } x < 0 \\ x & \text{for } x \geq 0 \end{cases}$	$f'(x) = \begin{cases} 0 & \text{for } x < 0 \\ 1 & \text{for } x \geq 0 \end{cases}$
Parameteric Rectified Linear Unit (PReLU) [2]		$f(x) = \begin{cases} \alpha x & \text{for } x < 0 \\ x & \text{for } x \geq 0 \end{cases}$	$f'(x) = \begin{cases} \alpha & \text{for } x < 0 \\ 1 & \text{for } x \geq 0 \end{cases}$
Exponential Linear Unit (ELU) [3]		$f(x) = \begin{cases} \alpha(e^x - 1) & \text{for } x < 0 \\ x & \text{for } x \geq 0 \end{cases}$	$f'(x) = \begin{cases} f(x) + \alpha & \text{for } x < 0 \\ 1 & \text{for } x \geq 0 \end{cases}$
SoftPlus		$f(x) = \log_e(1 + e^x)$	$f'(x) = \frac{1}{1 + e^{-x}}$



# Artificial neural networks (ANN)

Select an **architecture** (problem-dependent)

- Inputs, outputs, type and number of hidden layers, activation functions

Define a **cost** (loss) function


- Quadratic (Rumelhart), exponential, cross-entropy, KL divergence, etc.

Choose a **training** (learning) technique

- Back propagation (gradient-descent) algorithms, Newton's methods, Conjugate gradients, LM algorithm, etc.

## Regularization


- Norm penalty (L1, L2), early stopping, **dropout**, data augmentation, transfer learning, etc.




# Deep Learning (NN) Architectures




## Multi-layer neural perceptron (MLP)




## Convolutional Neural Network (CNN)




## Recurrent Neural Network (RNN)




## Autoencoders (AE)



## Generative adversarial networks (GAN)




# Example architecture: CNN




Kernel (Filter) parameters:



- Size (s)
- Depth: number of neurons
- Stride: amount of shift
- Zero-padding



## CNN- LeNet5 (1998)



## Alex Krizhevsky et al, 2012




Kawatsu, 2017





# Backpropagation algorithm: Gradient descent

- Basic gradient descent
  - $w_{i+1} = w_i - \eta \cdot \nabla C(w; (X, y))$
- Stochastic gradient descent (SGD)
  - $w_{i+1} = w_i - \eta \cdot \nabla C(w; (X_{\text{batch}}, Y_{\text{batch}}))$
- Other modifications
  - Momentums, accelerations, adaptive gradient (Adagrad), adaptive momentum (Adam), etc.



1. **Input x:** Set the corresponding activation  $a^1$  for the input layer.


2. **Feedforward:** For each  $l = 2, 3, \dots, L$  compute  $z^l = w^l a^{l-1} + b^l$  and  $a^l = \sigma(z^l)$ .

3. **Output error  $\delta^L$ :** Compute the vector  $\delta^L = \nabla_a C \odot \sigma'(z^L)$ .


4. **Backpropagate the error:** For each  $l = L - 1, L - 2, \dots, 2$  compute  $\delta^l = ((w^{l+1})^T \delta^{l+1}) \odot \sigma'(z^l)$ .

5. **Output:** The gradient of the cost function is given by

$$\frac{\partial C}{\partial w_{jk}^l} = a_k^{l-1} \delta_j^l \text{ and } \frac{\partial C}{\partial b_j^l} = \delta_j^l.$$




Modified from Nielsen, 2018







# Learning Regularization



## Early stopping



## Dropout




# What training sample size is required?




Introduction to Machine and Deep Learning for Medical Physicists

Sunan Cui,<sup>\*</sup> Huan-Hsin Tseng,<sup>†</sup> Julia Pakela,<sup>‡</sup> Randall K. Ten Haken,<sup>§</sup> and Issam El Naqa<sup>¶</sup>

*Department of Radiation Oncology, University of Michigan, Ann Arbor, MI 48103, USA*



# What evaluation plan for ML?



1 → 2 : knowledge of 1 is necessary for 2


1 - - - - -> 2 : feedback from 1 should be used to adjust 2

# AI/ML Validation

## Depending on the level of evidence

- Selection appropriate learning algorithms
- Validation and evaluation (**TRIPOD criteria**)
  - Internally (cross-validation schemes)
  - Externally (independent datasets)
- **Checklists:** CLAIM, MI-, CLAIM, CONSORT-AI, CLAMP, ...
- Provide **interpretation** of machine learning prediction

## Transparent Reporting of a multivariable prediction model for Individual Prognosis Or Diagnosis (TRIPOD)



Analysis Type	Description
Type 1a	Development of a prediction model where predictive performance is then directly evaluated using exactly the same data (apparent performance).
Type 1b	Development of a prediction model using the entire data set, but then using resampling (e.g., bootstrapping or cross-validation) techniques to evaluate the performance and optimism of the developed model. Resampling techniques, generally referred to as "internal validation", are recommended as a prerequisite for prediction model development, particularly if data are limited (6, 14, 15).
Type 2a	The data are randomly split into 2 groups: one to develop the prediction model, and one to evaluate its predictive performance. This design is generally not recommended or better than type 1b, particularly in case of limited data, because it leads to lack of power during model development and validation (14, 15, 16).
Type 2b	The data are nonrandomly split (e.g., by location or time) into 2 groups: one to develop the prediction model and one to evaluate its predictive performance. Type 2b is a stronger design for evaluating model performance than type 2a, because allows for nonrandom variation between the 2 data sets (6, 13, 17).
Type 3	Development of a prediction model using 1 data set and an evaluation of its performance on separate data (e.g., from a different study).
Type 4	The evaluation of the predictive performance of an existing (published) prediction model on separate data (13).

Types 3 and 4 are commonly referred to as "external validation studies." Arguably type 2b is as well, although it may be considered an intermediary between internal and external validation.

# Quality assurance for AI/ML application in the clinic

## Acceptance Testing

- To ensure that the ML tool meets all applicable safety and performance standards (prediction) and that it meets contractual specifications
- Manufacturer includes an acceptance test procedure with the ML tool
  - Selection of evaluation endpoint and definition of performance criteria (e.g., AUC);
  - Selection of a benchmark data

## Commissioning


- The process whereby the needed tool-specific data/parameters are acquired and operational procedures are defined
- May include:
  - Training data collection
  - Developing procedures
  - User training before first use

## Quality Assurance (QA)

- Effort to ensure treatments are given accurately, safely and efficiently according to established tests and evaluations


## Continuing Quality Improvement (CQI)

- Effort that seeks to make treatments and operations better by recognizing current weaknesses in the program, anticipating problems before they happen, streamlining tasks and responding to changes in practice

 **Table 10.1** Contemporary QA considerations for the current state of machine learning applications

TYPE OF MACHINE LEARNING APPLICATION	QA CONSIDERATIONS FOR THE CURRENT STATE			
	PERFORMED BY REVIEWED BY	COMMISSIONING	ROUTINE QA	RISK BEING MITIGATED
ML replaces human tasks: linear accelerator QA	Confirm functionality with sample QA data (Ritter et al. 2018)	<ul style="list-style-type: none"> <li>Evaluate ML against current clinic standards (Klein et al. 2009)</li> <li>Test limits of analytics such as by inserting errors into delivery tests or datasets for analysis, e.g., intentional leaf offset present in the measurement result but missing in the delivery file</li> <li>Document situations where the software passes and fails</li> <li>Document situations where results differ by &gt;5%</li> </ul>	<ul style="list-style-type: none"> <li>Frequency: monthly</li> <li>Monitor software settings for analysis</li> <li>Repeat analysis of a subset of the commissioning dataset (e.g., dynamic leaf gap) including one at the limit</li> <li>Expect identical results unless the software has changed.</li> <li>If software has changed, determine if a new baseline is needed</li> <li>Evaluate against a subset of the manual analysis for software updates</li> <li>Review trends</li> </ul>	<ul style="list-style-type: none"> <li>Confirm that the analysis is performed correctly to avoid the hazards of expectation bias</li> </ul>
ML supplemental to human tasks: treatment planning	<ul style="list-style-type: none"> <li>Confirm functionality with vendor-supplied treatment plans</li> <li>Define scope of ML for planning</li> </ul>	<ul style="list-style-type: none"> <li>Evaluate behavior against appropriate portions of original TPS commissioning results (if available) (Fraass et al. 1998)</li> <li>Are clinical goals met? Is the agreement within ±5% for key metrics, such as mean dose for targets and max dose to a volume (e.g., 1 cc)?</li> <li>Evaluate ML tools for a range of body sites and have site-specific rollout of techniques for at least a limited number of body sites</li> <li>Evaluate permissions of different user types for applying ML techniques (e.g., physicist vs. dosimetrist)</li> <li>Have different users perform the same test case—results within 5%?</li> <li>Establish procedures for quality control steps post-application of ML, e.g., MD and physicist review of final dose distribution</li> </ul>	<ul style="list-style-type: none"> <li>Repeat analysis of a subset of the commissioning dataset (e.g., dynamic leaf gap) including one at the limit</li> <li>Monitor key dosimetric results from ML techniques using Big Data Analytical tools where available by body site: e.g. target coverage and maximum dose to a volume (e.g., 1cc) for OARs (Mayo et al., 2017)</li> <li>Add extra scrutiny on key metrics for the first 5 patients per body site</li> </ul>	<ul style="list-style-type: none"> <li>Monitor for any unintentional shift in clinical practice due to settings in the ML algorithm</li> <li>Maintain evaluation of plan against MD-provided goals (planning objectives) (Evans et al. 2016; Marks et al. 2013)</li> </ul>

(continued next page)

 **Table 10.1 (continued)** Contemporary QA considerations for the current state of machine learning applications

TYPE OF MACHINE LEARNING APPLICATION	QA CONSIDERATIONS FOR THE CURRENT STATE			
	PERFORMED BY REVIEWED BY	COMMISSIONING	ROUTINE QA	RISK BEING MITIGATED
ML/AI enhances human tasks: patient workflow, such as preparation for optimization	Confirm functionality and understand the scope of what is automated	<ul style="list-style-type: none"> <li>Define if ML tools will be applied and implemented for all patients or by body site</li> <li>Create a commissioning dataset which includes manual preparation of the plan for optimization and automated preparation</li> <li>Confirm reasonably concordant results between human and automated creation</li> <li>Inspect the overlay of human vs. automated volumes to confirm expansions are correct</li> <li>Verify volumes for optimization are within 5% or 2 cc (for optic and other small structures)</li> </ul>	<ul style="list-style-type: none"> <li>Repeat a subset of the commissioning dataset</li> <li>Confirm derivative structures such as optimization structures are consistent with those by humans (monthly)</li> <li>Confirm that quality control steps post-application remain in place, such as review of the final dose distribution by MD and physicist</li> </ul>	<ul style="list-style-type: none"> <li>Risk being mitigated is an incorrect expansion from target or OAR volumes to create optimization structures for dose coverage or sparing, respectively</li> <li>Maintain evaluation of plan against MD provided goals (planning objectives) (Evans et al., 2016; Marks et al. 2013)</li> </ul>
ML additive: decision-making (El Naqa et al. 2018a)	<ul style="list-style-type: none"> <li>Evaluate with vendor-supplied dataset</li> <li>Define size of training and testing dataset</li> </ul>	<ul style="list-style-type: none"> <li>Partner with physicians to determine which disease types and staging are appropriate for the algorithm</li> <li>Assess baseline variation in clinical practice among physicians within a practice, within a registry, or via publications before implementation</li> <li>Assess sensitivity of the output of algorithms with training sets across the spectrum of limited variability to significant variability</li> <li>Is the algorithm supporting implementation of a national practice standard?</li> <li>Is the algorithm being used to apply new science in a clinical trial?</li> </ul>	<ul style="list-style-type: none"> <li>Confirm that the input and expected output are consistent with the intent of the practice</li> <li>Assess the frequency of patient type to determine how often the training dataset should be updated</li> <li>Monitor the relationship between decisions with prior practice using Big Data Analytical tools where available by body site</li> </ul>	




REVIEW ARTICLE | [Free Access](#)

## A review of explainable and interpretable AI with applications in COVID-19 imaging

Jordan D. Fuhrman , Naveena Gorre, Qiyuan Hu, Hui Li, Issam El Naqa, Maryellen L. Giger

First published: 18 November 2021 | <https://doi.org/10.1002/mp.15359>

Senior author: Maryellen L. Giger [m-giger@uchicago.edu](mailto:m-giger@uchicago.edu)





# ML Accuracy versus interpretability




Table 1. The evaluation of the accuracy (A), interpretability (I) and explainability (E) of ML approaches in radiation outcomes prediction


Basic ML	Type	A	I	E	Improved ML	Type	A	I	E
Logistic regression <sup>20,21</sup>	IP	*	****	***	GA <sup>2</sup> M <sup>68</sup>	IP	**	***	**
					Ridge Regression <sup>22</sup>	IP	**	**	*
					LASSO <sup>23</sup>	IP	**	***	**
					Elastic Net <sup>9,24</sup>	IP	***	**	*
Decision tree <sup>24,30,31</sup>	IP	**	*****	*****	CART <sup>32</sup>	IP	***	****	*****
					Random Forests <sup>7</sup>	NIP	****	*	NA
					GBM <sup>9,33</sup>	NIP	****	*	NA
					MediBoost <sup>9,34</sup>	IP	****	**	*
Naïve BN <sup>35,37</sup>	IP	*	****	****	HBN <sup>38,40</sup>	IP	**	***	**
					HBN-EK <sup>41</sup>	IP	**	****	***
Linear SVM <sup>24</sup>	NIP	**	**	*	SVM-RBF <sup>43</sup>	NIP	***	*	NA
					SVM-LRBF <sup>44</sup>	NIP	***	**	*
Deep learning <sup>49,50</sup>	NIP	****	*	NA	DL-HLV <sup>48,55,56</sup>	NIP	*****	**	NA
					DL-SA <sup>52,57</sup> / AM <sup>59,60</sup>	NIP	*****	**	NA
					DL-DHLR <sup>61-63</sup>	NIP	*****	***	NA
					DL-LIME <sup>69</sup>	NIP	*****	***	NA

BN, Bayesian network; CART, classification and regression tree; DHLR, disentangled hidden layer representation; DL-AM, deep learning with attention mechanisms; DL-HLV, deep learning with combination of handcrafted features and latent variables; GBM, gradient boosting machine; HBN, hierarchical Bayesian network; HBN-EK, hierarchical Bayesian network with expert knowledge; HLV, handcrafted features and latent variables; IP, interpretable; LASSO, least absolute shrinkage and selection operator; LIME, local interpretable model-agnostic explanation; ML, machine learning; NIP, non-interpretable; SVM, support vector machine.



# Deep learning interpretability approaches



## Post-modeling proxy Models



## Explainable Neural Networks (xNN) based on Additive Index Models



# Why interpretability important?



## Adversarial Attacks


Original image

Sylvester Stallone



Noise perturbation

Adversarial noise




Neural network  
Classification

Keanu Reeves






# ML/DL Interpretability




Luo, BJR-O, 2019

## Radiomics Interpretability for Liver Cancer (Grad-CAM)



## Multi-omics interpretability for Lung Cancer





# Some Popular ML/DL platforms


ML tools  
in Java



Google  
(py/C)



Interface  
(python)



Library  
(python)




Microsoft  
Cognitive  
Toolkit

theano

UdM  
(python)



Berkeley  
(py/C)





Torch  
(py/C)

PyTorch  
Facebook



Top Deep Learning Libraries, 2018



Source: KDnuggets




# An open source machine learning framework for everyone

```

TF1.py x
1 import tensorflow as tf
2 import numpy as np
3 import matplotlib.pyplot as plt
4
5 mnist = tf.keras.datasets.mnist
6
7 (x_train, y_train), (x_test, y_test) = mnist.load_data()
8 x_train, x_test = x_train / 255.0, x_test / 255.0
9
10
11 #plt.imshow(x_train[0], cmap=plt.cm.binary)
12 #print(x_train[0])
13 #plt.show()
14 model = tf.keras.models.Sequential([
15     tf.keras.layers.Flatten(),
16     tf.keras.layers.Dense(512, activation=tf.nn.relu),
17     tf.keras.layers.Dropout(0.2),
18     tf.keras.layers.Dense(10, activation=tf.nn.softmax)
19 ])
20 model.compile(optimizer='adam',
21               loss='sparse_categorical_crossentropy',
22               metrics=['accuracy'])
23
24 model.fit(x_train, y_train, epochs=5)
25 model.evaluate(x_test, y_test)
26 val_loss, val_acc = model.evaluate(x_test, y_test)
27 print(val_loss, val_acc)
28 prediction = model.predict([x_test])
29 print(prediction)
30 print(np.argmax(prediction[0]))
31 print(x_test[0])
32 plt.figure()
33 plt.imshow(x_test[0], cmap='gray')
34 plt.show()

```



Training

```

60000/60000 [=====]
Epoch 2/5
60000/60000 [=====]
Epoch 3/5
60000/60000 [=====]
Epoch 4/5
60000/60000 [=====]
Epoch 5/5
60000/60000 [=====]


```

Testing

```

10000/10000 [=====]
10000/10000 [=====] - 0s 39us/step
0.06758721045646235 0.9795

```



```

0.1997 - acc: 0.9412
0.0800 - acc: 0.9754
0.0513 - acc: 0.9833
0.0361 - acc: 0.9887
0.0263 - acc: 0.9914

```



# Take home Messages

- There are different classes of **ML/DL** algorithms with varying **accuracy** and **interpretability** levels and the choice of the proper algorithm(s) is a **problem and data** dependent
- Once an ML/DL algorithm is identified, a proper plan for **training** (sample size), **evaluation** (statistics), and **validation** (testing) should be developed to assure **generalizability** (out-of-sample)
- **Acceptance** and **commissioning** of ML/DL for medicine is in its infancy, however, efforts are being made by public and private sectors towards **safe** ML/DL implementation

# References



Deep Medicine: How Artificial Intelligence Can Make Healthcare Human Again, Basic Books, 2019

Machine Learning in Radiation Oncology: Theory and Applications. El Naqa, Li, Murphy (editors), Springer, 2015.

Emerging Developments and Practices in Oncology: El Naqa (Editor), IGI Global, Hershey, PA, 2018.

A Guide to Outcome Modeling In Radiotherapy and Oncology: Listening to the Data, El Naqa (Editor): CRC press: Taylor and Francis Group, Boca Raton, FL, USA, 2018.

Machine Learning with Radiation Oncology Big Data (eBook): Deng, El Naqa, Xing (Editors), Frontier in Oncology, Lausanne, Switzerland, 2019.

Machine and Deep Learning in Oncology, Medical Physics and Radiology: El Naqa, Murphy, Springer Nature, 2022.

## **Useful ML/DL websites:**

[Tensorflow](#). [CNTK](#).

<https://www.kaggle.com/>. [Scikit](#)



[Coursera: machine-learning](#)

# A GUIDE TO OUTCOME MODELING IN RADIATION THERAPY AND ONCOLOGY

LISTENING TO THE DATA

A GUIDE TO OUTCOME MODELING IN RADIATION THERAPY AND ONCOLOGY

## Machine and Deep Learning in Oncology, Medical Physics and Radiology



Collage of illustrations from papers from the Special Issue on Datasets hosted in The Cancer Imaging Archive (TCIA). Thanks to Jeff Tobler, University of Arkansas, for creating this collage.

Medical Physics is an official journal of the AAPM, the International Organization for Medical Physics (IOMP), and the Canadian Organization of Medical Physicists (COMPP).


# Moffitt Cancer Center: Why we are building the first machine learning department in oncology

By Issam El Naqa and Dana Rollison

May 2020 | Volume 47, Issue 5

## MEDICAL PHYSICS

The International Journal of Medical Physics Research and Practice



Collage of figures from articles in the Special Issue on 'The Role of Machine Learning in Modern Medical Physics', pp. e125-e126 (online only, free available).

Medical Physics is an official journal of the AAPM, the International Organization for Medical Physics (IOMP), and the Canadian Organization of Medical Physicists (COMPP).

# THANK YOU!